Presentations

Below are presentations given at recent medical or scientific conferences or meetings.

Treatment With Quizartinib (AC220) Enables a High Rate of Patients With Relapsed or Refractory FLT3-ITD(+) Acute Myeloid Leukemia to be Bridged to HSCT
The 19th Annual Meeting of the European Hematology Association
Milan, Italy
June 12–15, 2014
Download>

Quizartinib (AC220) in Patients With FLT3-ITD(+) Relapsed or Refractory Acute Myeloid Leukemia: Final Results of a Randomized Phase 2 Study
The 19th Annual Meeting of the European Hematology Association
Milan, Italy
June 12–15, 2014
Download>

Final Results of a Randomized Phase 2 Study Showing the Clinical Benefit of Quizartinib (AC220) in Patients with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia
American Society of Clinical Oncology 2014 Annual Meeting
Chicago, Illinois
June 2, 2014
Download>

The Benefit of Treatment with Quizartinib and Subsequent Bridging to HSCT for FLT3-ITD(+) Patients with AML
American Society of Clinical Oncology 2014 Annual Meeting
Chicago, Illinois
June 2, 2014
Download>

Results of Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML)
55th ASH Annual Meeting and Exposition
New Orleans, Louisiana
December 9, 2013
Download>

Results of Phase 1 Study of Quizartinib In Combination with Induction and Consolidation Chemotherapy in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia
55th ASH Annual Meeting and Exposition
New Orleans, Louisiana
December 9, 2013
Download>

Quizartinib Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Experience From The AML Pilot Trial
55th ASH Annual Meeting and Exposition
New Orleans, Louisiana
December 9, 2013
Download>

A Phase I Study of Quizartinib in Combination with Cytarabine and Etoposide in Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances in Childhood Leukemia & Lymphoma Study
55th ASH Annual Meeting and Exposition
New Orleans, Louisiana
December 9, 2013
Download>

High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation With Quizartinib (AC220) in Patients With FLT3-ITD– Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
European Hematology Association 2013 Annual Meeting Stockholm, Sweden
Download>

Efficacy and Safety of Quizartinib (AC220) in Patients Age ≥60 Years with FLT3-ITD Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
European Hematology Association 2013 Annual Meeting Stockholm, Sweden
Download>

High Response Rate and Bridging to Hematopoietic Stem Cell Transplantation With Quizartinib (AC220) in Patients With FLT3-ITD Positive or Negative Relapsed/Refractory AML After Second-Line Chemotherapy or Previous Bone Marrow Transplant (Poster #7012)
American Society of Clinical Oncology 2013 Annual Meeting
Chicago, Illinois
Download>

Quizartinib (AC220) Produces High Response Rates and Long-Term Survival in Elderly Patients With FLT3-ITD(+) or FLT3-ITD(–) Relapsed/Refractory Acute Myeloid Leukemia (Poster #7021)
American Society of Clinical Oncology 2013 Annual Meeting
Chicago, Illinois
Download>

Efficacy and Safety of Quizartinib (AC220) in Patients Aged ≥70 Years With FLT3 ITD(+) or FLT3 ITD(–) Relapsed/Refractory Acute Myeloid Leukemia (Poster #7023)
American Society of Clinical Oncology 2013 Annual Meeting
Chicago, Illinois
Download>